PRMT5 and breast carcinoma: We have recently shown that PRMT5 activates WNT/β‐CATENIN signalling pathway in three different types of non‐Hodgkin’s lymphoma cell lines, mouse primary lymphoma cell lines and clinical samples through epigenetic silencing of AXIN2 and WIF1. 37However, the role played by PRMT5 in regulating WNT/β‐CATENIN signalling in breast cancer remains unknown.